Targeting VEGFR-2 in Metastatic Gastric Cancer: Results From a Literature-Based Meta-Analysis

Roviello, Giandomenico; Połom, Karol; Roviello, Franco; Marrelli, Daniele; Multari, Andrea Giovanni; Paganini, Giovanni; Pacifico, Chiara; Generali, Daniele

doi:10.1080/07357907.2016.1276185

Cited by 14 publications

(11 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A significant impact of overall survival, which was increased, was detected. This study confirmed the anti-VEGFR-2 inhibitors, like apatinib and ramucirumab positive action [ 120 ].…”

Section: Factors That Influence High Progression Of Gastric Cancesupporting

confidence: 79%

“…Therefore, ramucirumab is the first FDA approved treatment for advanced gastric cancer after previously applied chemotherapy. Recently Roviello et al, 2017 [ 120 ] performed a meta-analysis to check the efficacy and the safety of the novel VEGFR-2 inhibitors among cases with metastatic gastric and gastroesophageal junction cancer. A meta-analysis that is based on the literature of randomized controlled trials (RCTs) was investigated.…”

Section: Factors That Influence High Progression Of Gastric Cancementioning

confidence: 99%

See 1 more Smart Citation

The Pattern of Signatures in Gastric Cancer Prognosis

Machlowska

Maciejewski

Sitarz

2018

IJMS

View full text Add to dashboard Cite

Gastric cancer is one of the most common malignancies worldwide and it is a fourth leading cause of cancer-related death. Carcinogenesis is a multistage disease process specified by the gradual procurement of mutations and epigenetic alterations in the expression of different genes, which finally lead to the occurrence of a malignancy. These genes have diversified roles regarding cancer development. Intracellular pathways are assigned to the expression of different genes, signal transduction, cell-cycle supervision, genomic stability, DNA repair, and cell-fate destination, like apoptosis, senescence. Extracellular pathways embrace tumour invasion, metastasis, angiogenesis. Altered expression patterns, leading the different clinical responses. This review highlights the list of molecular biomarkers that can be used for prognostic purposes and provide information on the likely outcome of the cancer disease in an untreated individual.

show abstract

“…A significant impact of overall survival, which was increased, was detected. This study confirmed the anti-VEGFR-2 inhibitors, like apatinib and ramucirumab positive action [ 120 ].…”

Section: Factors That Influence High Progression Of Gastric Cancesupporting

confidence: 79%

Section: Factors That Influence High Progression Of Gastric Cancementioning

confidence: 99%

The Pattern of Signatures in Gastric Cancer Prognosis

Machlowska

Maciejewski

Sitarz

2018

IJMS

View full text Add to dashboard Cite

show abstract

“…Rivoceranib has been approved in China for use as a single or combination therapy for various end-stage solid cancers including stomach, colorectal, liver, and adenoid cyst carcinoma [18,20,22]. This small-molecule receptor TKI can block the phosphorylation of VEGFR-2 by binding its intracellular adenosine triphosphate sites [18,19,20].…”

Section: Discussionmentioning

confidence: 99%

“…The effectiveness of rivoceranib has already been proven in metastatic solid cancer, including gastric, colorectal, hepatocellular, and lung cancer [18,20,22]. Thus, we thought that rivoceranib could be a potential therapeutic agent in CNV.…”

Section: Introductionmentioning

confidence: 97%

Comparison of the Therapeutic Efficacies of Topical Rivoceranib and Topical Bevacizumab in a Murine Model of Corneal Neovascularization

Yoon

Woo

et al. 2019

Medicina

View full text Add to dashboard Cite

Background and Objectives: Corneal neovasculariziation (CNV) is a serious vision-threatening complication; however, all therapeutics have their clinical limitations. The aim of this study is to investigate the efficacy of topical rivoceranib compared with topical bevacizumab in a murine model of corneal neovascularization (CNV). Materials and Methods: Murine CNV was induced by means of total de-epithelization and alkali burn. Mice were divided into five groups according to topical treatment: untreated control, phosphate-buffered saline (PBS), 0.1% and 0.5% rivoceranib, and 0.5% bevacizumab. CNV area and index were measured 7 and 14 days after treatment. After corneal tissues were excised at day 14, the blood and lymphatic vessels were quantified by cluster of differentiation 31 (CD31) and lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1) immunofluorescence, respectively. Results: After 14 days, treatment groups with 0.1% and 0.5% rivoceranib and 0.5% bevacizumab showed a decrease in CNV area and index compared with the untreated and PBS groups (all p < 0.01). Blood and lymphatic vascularization significantly decreased in the 0.5% rivoceranib and 0.5% bevacizumab groups, as measured by CD31 and LYVE1 immunofluorescence. There was no significant difference of vascularization between the 0.5% rivoceranib and bevacizumab groups. Conclusions: Topical application of rivoceranib could effectively decrease CNV equivalent to topical bevacizumab in a murine model.

show abstract

“…This study represents an important step forward in gastric cancer study, because it proved the value of targeting VEGFR drugs, including VEGFR-Ab and VEGFR-TKI, on the basis of available evidence that supports the use of ramucirumab [ 43 ]. More recently, a mate-analysis of five trials on targeting VEGFR-2 in a total of 1,596 patients with advanced gastric cancer demonstrated that anti-VEGFR-2 inhibitors revealed a significant increase in OS [HR: 0.69, 95% CI (0.55, 0.87) p = 0.002] [ 44 ]. However, this analysis, which included only a small number of trials and only studied VEGFR-2, cannot reflect the overall efficacy of targeting VEGFR drugs and did not have a subgroup analysis to detect the cause of high heterogeneity.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of targeting VEGFR drugs in treatment for advanced or metastatic gastric cancer: a systemic review and meta-analysis

et al. 2017

View full text Add to dashboard Cite

The value of targeting VEGFR (vascular endothelial growth factor receptor) drugs has demonstrated encouraging anti-cancer activity in advanced solid tumors within current clinical trials. This study aimed to serve as the first systemic review to assess their safety and efficacy according to biochemical characteristics of targeting VEGFR drugs in gastric cancer. We analyzed eight clinical trials on targeting VEGFR drugs in gastric cancer. Results showed that targeting VEGFR drugs significantly improved overall survival (OS) [Hazard Ratio (HR) 0.69, 95% confidence interval (CI) (0.55, 0.83), P < 0.001], progression free survival (PFS) [HR 0.50, 95% CI (0.34, 0.66), P < 0.001], disease control rate (DCR) [Odds Ratio (OR) 3.83, 95% CI (2.39, 6.15), P < 0.001] and significantly decreased the progressive disease rate(PDR)[OR 0.45, 95% CI (0.34, 0.59), P < 0.001], but not objective response rate (ORR) [OR 1.46, 95% CI (0.93, 2.29), P = 0.098]. Further subgroup revealed that VEGFR antibody (VEGFR-Ab) drugs were superior to VEGFR tyrosine kinase inhibitor (VEGFR-TKI) drugs in terms of the OS, PFS and PDR. To determine the toxic effect of targeting VEGFR drugs, the relative risk of adverse events (grade ≥ 3) of special interest(AESIs) were estimated. Most of these were predictable and manageable. Furthermore, less AESIs were observed in the VEGFR-Ab than the VEGFR-TKI drugs. In conclusion, VEGFR drugs were effective targeted therapy in advanced or metastatic gastric cancer, and its toxicity is within a controllable range. VEGFR-Ab drugs were more effective than VEGFR-TKI drugs in terms of the OS, PFS and PDR of gastric cancer patients with little toxicity.

show abstract

Targeting VEGFR-2 in Metastatic Gastric Cancer: Results From a Literature-Based Meta-Analysis

Cited by 14 publications

References 25 publications

The Pattern of Signatures in Gastric Cancer Prognosis

The Pattern of Signatures in Gastric Cancer Prognosis

Comparison of the Therapeutic Efficacies of Topical Rivoceranib and Topical Bevacizumab in a Murine Model of Corneal Neovascularization

Efficacy and safety of targeting VEGFR drugs in treatment for advanced or metastatic gastric cancer: a systemic review and meta-analysis

Contact Info

Product

Resources

About